Last reviewed · How we verify
Methyllorazepam (LORMETAZEPAM)
Lormetazepam works by enhancing the activity of a neurotransmitter called GABA, which helps to calm the brain and induce sleep.
Lormetazepam, a small molecule belonging to the drug class of lormetazepam, is a benzodiazepine derivative. It is used to treat insomnia and other sleep disorders. The commercial status of lormetazepam is not explicitly stated, but it is likely available as a generic medication. Lormetazepam has a half-life of 4.9 hours and a bioavailability of 75%. Its exact target and approved indications are unknown.
At a glance
| Generic name | LORMETAZEPAM |
|---|---|
| Drug class | lormetazepam |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Imagine your brain is like a busy city with lots of noise and activity. GABA is like a traffic cop that helps to slow down the traffic and calm things down. Lormetazepam helps GABA to do its job more effectively, making it easier to fall asleep and stay asleep.
Approved indications
Common side effects
- Coma
- Drug abuse
- Poisoning deliberate
- Drug dependence
- Sopor
- Somnolence
- Miosis
- Toxicity to various agents
- Suicide attempt
- Drug interaction
- Serotonin syndrome
- Overdose
Key clinical trials
- Electroencephalography and Sleep Quality With Lormetazepam in the Intensive Care Unit
- Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care (PHASE4)
- Lormetazepam Versus Midazolam in Critically Ill Patients: a Retrospective Cohort Trial
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties (PHASE3)
- Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methyllorazepam CI brief — competitive landscape report
- Methyllorazepam updates RSS · CI watch RSS